Azaepothilone B and its derivatives: a patent review

References

• Gw Pharma Ltd. Phytocannabinoids for use in the treatment of breast cancer. US20140314757A1. 2014.
   Google Scholar
• Chih HL Herbal composition for treating metastatic breast cancer. US20140295006A1. 2014.
   Google Scholar
• O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20–29.
   PubMed Web of Science ®Google Scholar
• Bipar Sciences, Inc. Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan. US20130274281A1. 2013.
   Google Scholar
• Colozza M, de Azambuja E, Cardoso F, et al. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist. 2006;11(2):111–125.
   PubMed Web of Science ®Google Scholar
• Palmieri FM, Hopkins U. Ixabepilone, a new class of chemotherapy for advanced breast cancer. Cancer Therapy. 2004;7:153–162.
   Google Scholar
• Vahdat L. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. The Oncologist. 2008;13:214–221.
   PubMed Web of Science ®Google Scholar
• The University Of Utah Research Foundation. Paclitaxel trihydrates and methods of making thereof. US8633240B2 . 2014.
   Google Scholar
• Haar E, Kowa Lski RJ, Hamel E, et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than Taxol. Biochemistry. 1996;35:243–250.
   PubMed Web of Science ®Google Scholar
• Lindel T, Jen Sen PR, Fenical W, et al. Eleutherobin,a new cytotoxin that mimics paclitaxel (Taxol) by stabilizing microtubules. J Am Chem Soc. 1997;119:8744–8745.
   Web of Science ®Google Scholar
• Nicolaou KC, Winssinger N, Vourloumis D, et al. Solid and solution phase synthesis and biological evaluation of combinatorial sarcodictyin libraries. J Am Chem Soc. 1998;120:10814–10826.
   Web of Science ®Google Scholar
• Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. PNAS. 2000;97(6):2904–2909.
   PubMed Web of Science ®Google Scholar
• Hofle G, Glaser N, Kiffe M, et al. N-Oxidation of Epothilone A–C and O-Acyl Rearrangement to C-19- and C-21-Substituted epothilones. Angew Chem Int Ed. 1999;38(13–14):1971–1974.
   Web of Science ®Google Scholar
• Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995;55:2325–2333.
   PubMed Web of Science ®Google Scholar
• Su D-S, Balog A, Meng D, et al. Structure–activity relationship of the epothilones and the first in vivo comparison with paclitaxel. Angew Chem Int Ed Engl. 1997;36:2093–2096.
   Web of Science ®Google Scholar
• Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 7:1429–1437.
   PubMed Web of Science ®Google Scholar
• Florshmer A, Altman K. Epothilones and analogues – a new class of promising microtubule inhibitors. Expert Opin Ther Patents. 2001;11(6):951–968.
   Web of Science ®Google Scholar
• Ixempra. Rx List owned and operated by WebMD, USA. Available at http://www.rxlist.com/ixempra-drug.htm [Cited on Feb 28, 2016]
   Google Scholar
• Aghajanian C, Burris HA, Jones S, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol. 2007;25(9):1082–1088.
   PubMed Web of Science ®Google Scholar
• Ixempra. Bristol-Myers Squibb Co, USA. 2011. Available at http://packageinserts.bms.com/pi/pi_ixempra.pdf. [Cited onFeb 28, 2016].
   Google Scholar
• Bristol-Myers Squibb Co. Methods for the Preparation, Isolation and Purification of Epothilone B, and X-Ray Crystal Structures of Epothilone B. WO2004026254A1. 2004.
   Google Scholar
• Bristol-Myers Squibb Company. A Process for the Preparation of Ring-Opened Epothilone Intermediates which are useful for the preparation of Epothilone Analogs. WO9927890A2. 1999.
   Google Scholar
• Bristol-Myers Squibb Co. 12,13-Modified Epothilone Derivatives. WO9954319A1. 1999.
   Google Scholar
• Bristol-Myers Squibb Co. Epothilone Derivatives. WO2002098868A1. 2002.
   Google Scholar
• Bristol-Myers Squibb Co. Process for the Preparation of Epothilone Analogs. US6518421B1. 2003.
   Google Scholar
• Bristol-Myers Squibb Co. Process for the reduction of oxiranyl epothilones to olefinic epothilones. US6320045B1. 2001.
   Google Scholar
• Taizhou Jinzhao Weiye Fine Chem Ind Co Ltd. Method for biochemically synthesizing epothilone D-Lactam derivatives. CN101906099A. 2010.
   Google Scholar
• Taizhou Jinzhao Weiye Fine Chemical Industry Co Ltd. Chemical synthesis method of epothilone B-Lactam derivative. CN101880284A. 2010.
   Google Scholar
• Xellia Pharmaceuticals Aps. Manufacturing of epothilone derivatives and the use thereof. WO2013008091A1. 2013.
   Google Scholar
• Xellia Pharmaceuticals Aps, Bjoernstad V, Heggelund A Process for preparation of ixabepilone and intermediates useful in said process. WO2013164102A1. 2013.
   Google Scholar
• Kosan Biosciences Inc, Ashley G, Metcalf B. Epothilone derivatives and methods for making and using the same. US20030023082A1. 2003.
   Google Scholar
• Jialin Y. Synthetic method for natural product epsilon B lactam derivative. CN1554659A. 2004. .
   Google Scholar
• Chengdu Mol Biopharmaceutical Co Ltd. Preparation method of epothilone B lactam derivatives. CN103936748A. 2014.
   Google Scholar
• Tang L, Qiu R. Epothilone compounds, preparation method and use thereof. US2012322838A1. 2014.
   Google Scholar
• Beijing Huahao Zhongtian Biotechnology Co. Ltd. Novel epothilones compound as well as preparation method and use thereof. CN101177425B. 2012.
   Google Scholar
• Sloan-Kettering Institute for Cancer Research, USA. Synthesis of epothilones, intermediates thereto and analogues thereof. WO2001064650A2. 2001.
   Google Scholar
• Danishefsky, S J. et al. Synthesis of epothilones, intermediates thereto and analogues thereof. US20020058286A1. 2002.
   Google Scholar
• Sloan-Kettering Institute For Cancer Research, Danishefsky S J, Rivkin A, et al. Synthesis of epothilones, intermediates thereto, analogues and uses thereof. US7384964B2. 2008.
   Google Scholar
• Shenzhen Jatie Pharmaceutical Co Ltd. Ixabepilone Total Synthesis. CN103275091A. 2013.
   Google Scholar
• Bristol-Myers Co. Epothilone derivative. US6605599B1. 1999.
   Google Scholar
• Scinopharm Taiwan, Ltd. process for ixabepilone, and intermediates thereof. WO2014136099A1. 2014.
   Google Scholar
• Kosan Biosciences Inc, Ashley G, Fardis M, et al. Epothilone derivatives and methods for making and using the same. WO0192255A3. 2002.
   Google Scholar
• Novartis AG Epothilone derivatives. US7317100B2. 2008.
   Google Scholar
• Crasto AM. Polymorph case study… duvelisib [cited 2016 Feb 28]. Available at http://newdrugapprovals.org/2015/08/31/polymorph-case-study-duvelisib/.
   Google Scholar
• Bristol-Myers Squibb Company. Polymorphs of an epothilone analog. US7153879B2. 2006.
   Google Scholar
• Plus Chemicals Sa, Teva Pharmaceuticals USA Inc. Solid State forms of Ixabepilone. WO2011153221A1. 2011.
   Google Scholar
• Zhejiang Hisun Pharm Co Ltd. Crystal form of Ixabepilone and the Preparation Method and Use Thereof. WO2014135043A1. 2014.
   Google Scholar
• Schering AG, Skuballa W, Gay J, et al. radioactively labeled epothilone derivatives, method for the production thereof, and their biochemical and pharmaceutical use. WO0166154A2. 2001.
   Google Scholar
• Schering AG. New 13-Halo Or cyano-epothilone derivatives are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease. DE10020517A1. 2001.
   Google Scholar
• Schering AG. 6-Alkenyl-, 6-Alkinyl- and 6-Epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations. US2010168179A1. 2010.
   Google Scholar
• Kosan Biosciences Inc. 14-Methyl-Epothilones. WO03045324A3. 2004.
   Google Scholar
• ETH Zuerich, Karl-Heinz A, Fabian F, et al. 12-Aza-Ep0thil0nes, process for their preparation and their use as antiproliferative agents. WO2007110214A1. 2007.
   Google Scholar
• Llc P. Deuterium-enriched ixabepilone. US2009076099A1. 2009.
   Google Scholar
• Bristol-Myers Squibb Co, Bandyopadhyay R, Malloy T, et al. Parenteral formulation for epothilone analogs. US7022330B2. 2002.
   Google Scholar
• Bristol-Myers Squibb Co, Haby T, Gogate U S, et al. Process and formulation containing epothilones and analogs thereof. US20050171167A1. 2005.
   Google Scholar
• Bristol-Myers Squibb Co, Elan Pharma Int Ltd. Nanoparticle dispersion containing lactam compound. EP1773335A4. 2011.
   Google Scholar
• Bristol Myers Squibb Co, Naringrekar V, Comezoglu F T, et al. Methods for Administering Ixabepilone. WO2006105399A1. 2006.
   Google Scholar
• Bristol-Myers Squibb Co. Enteric coated bead comprising ixabepilone. EP1817013B1. 2008.
   Google Scholar
• Bristol-Myers Squibb Co. Pharmaceutical dosage forms of epothilones for oral administration. WO2002058701A1. 2002.
   Google Scholar
• Bristol-Myers Squibb Co, Lee D, Lee F Y. et al. Oral administration of ixabepilone. WO2009089138A1. 2009.
   Google Scholar
• Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery. WO2011031865A1. 2011.
   Google Scholar
• Cerulean Pharma Inc, Eliasof S. Compositions and Methods for Treatment of Autoimmune and Other Disease. US2012064107A1. 2012.
   Google Scholar
• Cerulean Pharma Inc. Cyclodextrin-Based Polymers for Therapeutic Delivery. US2013196906A1. 2013.
   Google Scholar
• Bayer Schering Pharma AG; Fischer K,C. Functionalised solid polymer nanoparticles containing epothilones. WO2009074274A1. 2009.
   Google Scholar
• Bayer Schering Pharma AG. Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer. EP2210584A1. 2010.
   Google Scholar
• Abraxis Bioscience Inc; Yang A, Tao C, et al. Compositions and methods for the preparation and administration of poorly water soluble drugs. WO2006034147A3. 2006.
   Google Scholar
• Bdr Pharm Int Pvt Ltd. Lyophilized ixabepilone pharmaceutical compositions. IN201400083I3. 2014.
   Google Scholar
• Brilliant Biomedical Technology (Suzhou) Co. Ltd. Nobuyasu Pharmaceuticals (Suzhou) Co., Ltd. Ixabepilone albumin freeze-dried composition and preparation method thereof. CN103908432A. 2014.
   Google Scholar
• Bristol-Myers Squibb Company, Lee FY. Treatment of refractory tumors using epothilone derivatives. WO02066038A1. 2002.
   Google Scholar
• Schering AG. Use of epothilones in the treatment of brain diseases associated with proliferative processes. EP1340498A1. 2003.
   Google Scholar
• Bristol-Myers Squibb Co. Methods for treating cancer in patients having breast cancer resistance protein overexpression. US20110112155A1. 2011.
   Google Scholar
• Univ. Emory, Univ. Cornell, Virginia Tech Intell Prop, et al. Non-myelosuppressive compounds, pharmaceutical compositions thereof, and methods of treatment. WO2009146152A3. 2010.
   Google Scholar
• Bristol-Myers Squibb Co, David L, Voi M, et al. Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases. WO03105828A1. 2003.
   Google Scholar
• Bristol-Myers Squibb Co, Lee FY. Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases. US7312237B2. 2007.
   Google Scholar
• Bristol-Myers Squibb Co, Cohen M. Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals. WO2007140299A3. 2008.
   Google Scholar
• Bristol-Myers Squibb Co, Jure-Kunkel M. Combination of Anti-Ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases. WO2009089260A3. 2009.
   Google Scholar
• Bristol-Myers Squibb Co. Combination of Anti-Ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases. US2014323533A1. 2014.
   Google Scholar
• Genzyme Corporation. Combination therapy for treating breast cancer. US8911736B2. 2014.
   Google Scholar
• Dietrich Silivia A. Total synthesis and biological activity of new functionalized epothilones for prodrug design and tumor targeting [dissertation submitted for Ph.D thesis]. Zurich: ETH Zurich; 2010.
   Google Scholar
• Xufen Y, Sun D. Macrocyclic drugs and synthetic methodologies toward macrocycles. Molecules. 2013;18:6230–6268.
   PubMed Web of Science ®Google Scholar
• Kim E, Moore BS, Yoon YJ. Reinvigorating natural product combinatorial biosynthesis with synthetic biology. Nat Chem Biol. 2015;11:649–659.
   PubMed Web of Science ®Google Scholar
• Borzilleri RM, Zheng X, Schmidt RJ, et al. A novel application of a Pd(0)-Catalyzed nucleophilic substitution reaction to the regio- and stereoselective synthesis of lactam analogues of the epothilone natural products. J Am Chem Soc. 2000;122:8890–8897.
   Web of Science ®Google Scholar
• Park SR, Park JW, Jung WS, et al. Heterologous production of epothilones B and D in Streptomyces venezuelae. Appl Microbiol Biotechnol. 2008 Nov;81(1):109–117.
   PubMed Web of Science ®Google Scholar
• Park SR, Han AR, Ban YH, et al. Genetic engineering of macrolide biosynthesis: past advances, current state, and future prospects. Appl Microbiol Biotechnol. 2010 Feb;85(5):1227–1239.
   PubMed Web of Science ®Google Scholar
• Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist. 2007;12(3):271–280.
   PubMed Web of Science ®Google Scholar
• Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210–5217.
   PubMed Web of Science ®Google Scholar
• Roque DM, Ratner ES, Silasi DA, et al. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review. Gynecol Oncol. 2015;137(3):392–400.
   PubMed Web of Science ®Google Scholar
• Zhang B, Carroll J, Trojanowski J, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci. 2012;32(11):3601–3611.
   PubMed Web of Science ®Google Scholar